Before Respiratory Volumes Accelerate: Review Influenza-Testing Rules With Your Providers

‍

Respiratory season has a way of exposing every inconsistency in an urgent care center’s clinical workflows.

When volumes are manageable, providers may take slightly different approaches to influenza testing without creating obvious operational problems. Once waiting rooms fill, however, those differences can lead to unnecessary testing, missed treatment opportunities, inconsistent patient education, avoidable delays, and confusion among clinical staff.

Before influenza activity and respiratory visit volumes accelerate, urgent care leaders should bring providers together to review one fundamental question:

‍

When should we test a patient for influenza—and how will the result change what we do?

‍

A brief clinical review now can help create faster, more consistent decision-making throughout the respiratory season.

‍

Influenza Testing Should Have a Clinical Purpose

Influenza testing should not become an automatic response to every patient presenting with fever, cough, congestion, or body aches.

Testing is most valuable when the result is reasonably expected to influence:

• Antiviral treatment decisions
• Additional diagnostic testing
• Antibiotic stewardship
• Infection-control precautions
• Return-to-work or return-to-school guidance
• Management of high-risk household contacts
• Evaluation of an institutional or community outbreak
• The patient’s overall plan of care

During periods of known influenza circulation, an otherwise healthy patient with a classic, uncomplicated presentation may be diagnosed clinically. Conversely, testing may provide greater value when the diagnosis is uncertain, the patient is at increased risk for complications, symptoms are severe or progressive, or the result will help distinguish influenza from another circulating respiratory illness.

The goal is not to test more patients or fewer patients. The goal is to test the right patients for the right reasons.

‍

Make Sure Providers Understand Which Influenza Test Is Being Used

Not all influenza tests perform the same way. Every provider should know whether the urgent care center uses:

• A rapid influenza diagnostic test that detects viral antigens
• A rapid molecular influenza assay
• A multiplex molecular test that detects influenza, COVID-19, RSV, or other respiratory pathogens
• A test that requires confirmation or referral to an outside laboratory

Rapid antigen influenza tests can produce results quickly, but they are generally less sensitive than molecular assays. A negative antigen test does not always exclude influenza—particularly when community influenza activity is high and the patient’s presentation is strongly suggestive of the disease.

CDC information indicates that many office-based rapid antigen tests have approximately 50%–70% sensitivity, although specificity is generally greater than 90%. Molecular assays offer higher sensitivity and specificity, and IDSA recommends rapid molecular assays over rapid antigen tests when testing outpatients for influenza.

Providers should therefore avoid treating every negative result as definitive. The result must be interpreted alongside:

• Current influenza activity
• Symptom onset
• Patient age and risk factors
• Specimen quality
• The specific test’s performance characteristics
• The clinical likelihood of influenza

‍

Review the Timing of Specimen Collection

The timing and quality of specimen collection can materially affect test performance.

For rapid influenza diagnostic testing, respiratory specimens should generally be collected as early as possible—ideally within the first three to four days after illness begins. Providers and clinical support staff must also follow the test manufacturer’s requirements regarding the appropriate specimen type, collection technique, transport, handling, and processing.

Before respiratory volumes increase, urgent care leaders should verify that:

• Staff are using the correct collection devices.
• Specimens are obtained from the approved anatomical site.
• Collection technique is standardized.
• Tests are processed within the permitted time frame.
• Quality-control procedures are current.
• Staff follow the manufacturer’s instructions and the center’s CLIA requirements.
• Providers understand how collection timing affects interpretation.

A reliable testing strategy depends on more than choosing the right test. It also depends on collecting the right specimen correctly.

‍

A Negative Rapid Test Does Not Always Mean “No Flu”

This is one of the most important points to reinforce with providers.

When influenza is circulating widely, a negative rapid antigen result may be a false negative. If the patient has a convincing clinical presentation—especially if the patient is at high risk for complications—the provider should not automatically rule out influenza based solely on a negative rapid antigen test.

Depending on the clinical circumstances, the provider may need to:

• Make a clinical diagnosis despite the negative result
• Initiate empiric antiviral treatment
• Obtain or send a molecular test
• Evaluate for another respiratory infection
• Assess for pneumonia or another complication
• Provide explicit follow-up and escalation instructions

CDC guidance states that clinically indicated antiviral treatment should not be withheld solely because a rapid antigen influenza test is negative.

Your urgent care protocol should clearly explain how providers are expected to respond when the clinical picture and test result do not agree.

‍

Do Not Delay Antiviral Treatment in High-Risk Patients

Testing and treatment are related, but they are not the same decision.

CDC guidance indicates that antiviral treatment should not be delayed while awaiting laboratory confirmation when influenza is suspected in patients for whom treatment is clinically indicated. This includes patients with severe or progressive illness and those at increased risk for influenza-related complications.

During the provider review, discuss how your organization will approach patients such as:

• Young children, especially those under age two
• Adults age 65 and older
• Pregnant or recently postpartum patients
• Immunocompromised patients
• Patients with significant pulmonary, cardiac, neurologic, metabolic, renal, or hepatic conditions
• Patients with severe obesity
• Patients with progressive symptoms or suspected influenza complications

Providers should understand that the value of antiviral treatment is generally greatest when treatment begins early. However, later treatment may still be appropriate for high-risk patients and those with severe or progressive illness.

‍

Account for Co-Circulating Respiratory Illnesses

Influenza rarely circulates alone. COVID-19, RSV, and other respiratory pathogens may cause overlapping symptoms, and coinfection is possible.

A positive influenza result does not automatically exclude COVID-19. Likewise, a positive COVID-19 result does not necessarily exclude influenza. When the distinction will affect treatment or disposition, multiplex molecular testing may offer an operational and clinical advantage.

Urgent care leaders should establish when providers are expected to order:

• Influenza-only testing
• Combined influenza and COVID-19 testing
• Influenza, COVID-19, and RSV testing
• Broader respiratory panels
• No respiratory testing

This decision should reflect the patient’s risk, presentation, local disease activity, available treatments, test performance, cost, and whether the result will meaningfully alter care.

‍

Strengthen Documentation and ICD-10-CM Code Selection

Influenza testing is only one part of the encounter. The provider’s documentation must clearly support the diagnosis, medical necessity of the testing, treatment decisions, and ICD-10-CM codes submitted on the claim.

A complete respiratory visit note should include:

• The patient’s primary complaint
• Symptom onset, duration, and progression
• Relevant symptoms and pertinent negatives
• Known influenza, COVID-19, RSV, household, or occupational exposures
• Relevant chronic conditions and risk factors for complications
• Examination findings and the patient’s overall clinical severity
• The type of test performed and its result
• The provider’s interpretation of the result
• The final clinical assessment
• The rationale for prescribing or withholding antiviral medication
• Evaluation for pneumonia or other complications when indicated
• Follow-up instructions, isolation guidance, and warning signs requiring escalation

‍

Match the ICD-10-CM Code to the Final Diagnosis

Providers should document the condition to the highest degree of certainty supported at the conclusion of the visit. The selected ICD-10-CM code should reflect the provider’s final assessment—not simply the test that was ordered or the symptoms entered during intake.

For outpatient encounters, conditions documented only as “probable,” “suspected,” “possible,” “questionable,” or “rule out” generally should not be reported as confirmed diagnoses. When no definitive diagnosis is established, the practice should code the signs and symptoms chiefly responsible for the visit, such as fever, cough, sore throat, fatigue, or myalgia, as appropriate.

When influenza is established, the documentation should identify, when known:

• Whether the influenza virus was identified
• Whether pneumonia is present
• Whether other respiratory manifestations are present
• Whether gastrointestinal or other manifestations are present
• Whether another respiratory infection was also diagnosed

Influenza code selection may fall within categories J09, J10, or J11, depending on whether the virus is identified and the manifestations documented. Codes from J09 and J10 should be used only when the applicable influenza diagnosis is confirmed. Providers should avoid selecting a highly specific influenza code when the medical record or test result does not support that specificity.

‍

Avoid Common Influenza Coding Problems

Common documentation and coding issues include:

• Coding confirmed influenza when the provider documented only “possible flu”
• Using an influenza diagnosis solely because a test was ordered
• Failing to update the diagnosis after receiving the test result
• Reporting a virus-specific code without documentation identifying the virus
• Failing to document pneumonia or another significant manifestation
• Coding symptoms that are routinely associated with confirmed influenza when they do not require separate reporting
• Using an unspecified code when the documentation supports a more specific diagnosis
• Reporting a screening or exposure code when the patient is symptomatic and being evaluated for an active illness
• Failing to connect the test result to the assessment and treatment plan

Diagnosis codes should tell the same clinical story as the provider’s note. When the documentation, test result, assessment, and claim do not align, the practice faces a greater risk of denials, payer questions, inaccurate quality reporting, and audit exposure.

Before respiratory volumes increase, urgent care organizations should review their preferred diagnosis lists, order sets, clinical templates, and coding workflows. Providers should also have a clear process for correcting or clarifying documentation when a final laboratory result changes the diagnosis after the initial encounter.

Thorough documentation and accurate ICD-10-CM coding protect more than reimbursement. They create a defensible medical record, support continuity of care, and provide more reliable clinical and operational data for the urgent care organization.

‍

Review Patient Communication

Patients may assume that every respiratory illness requires testing or that a negative result conclusively rules out influenza. Providers and staff should be prepared to explain:

• Why testing is or is not recommended
• What type of test is being used
• What a positive or negative result means
• Why treatment may be started without a positive test
• Why antibiotics do not treat influenza
• When the patient should seek reevaluation
• Which symptoms require emergency care
• How to reduce transmission to others

Consistent explanations improve the patient experience and reduce confusion when different family members receive different testing recommendations based on their ages, risks, symptoms, or duration of illness.

‍

Conduct a Brief Preseason Provider Review

An effective influenza-testing review does not need to become a lengthy meeting. A focused 10- to 15 -minute session can address the highest-risk areas.

Use the meeting to confirm:

1. Which influenza tests are available at each location?
2. When should providers test—and when is clinical diagnosis reasonable?
3. Which patients are at increased risk for complications?
4. How should providers interpret a negative rapid antigen result?
5. When should molecular or multiplex testing be used?
6. When should antiviral treatment begin without waiting for test confirmation?
7. What documentation is required?
8. What patient education should be included?
9. How will local influenza activity be communicated to providers?
10. Who is responsible for updating the protocol when guidance or test availability changes?

Clinical protocols should also be reviewed by your medical director and aligned with current CDC guidance, test-manufacturer instructions, CLIA requirements, state laws, payer requirements, and the organization’s internal policies.

‍

Consistency Before Volume Is the Best Strategy

Respiratory season is not the ideal time to discover that providers interpret influenza tests differently, staff use inconsistent collection techniques, or patients receive conflicting treatment guidance.

A preseason review gives the entire urgent care team a shared clinical framework before volumes intensify. The result should be a testing strategy that supports sound medical decision-making, efficient patient flow, appropriate antiviral use, antibiotic stewardship, defensible documentation, and a more consistent patient experience.

The most effective influenza-testing policy is not simply a rule about who receives a test. It is a coordinated approach that helps providers answer three questions:

Will the test provide reliable information? Will the result change management? And will the patient receive timely care regardless of the result?

If you would like more information on how your urgent care center can prepare for the upcoming flu season, contact us at sales@urgentiq.com

‍